Retatrutide is an investigational once-weekly "triple-G" peptide agonist currently in
Phase 3 clinical trials. It uniquely targets three metabolic hormone receptors—GLP-1, GIP , and glucagon—to suppress appetite, stimulate insulin, and increase energy expenditure, resulting in an average body weight reduction of up to 30%.
Unlike traditional GLP-1 and dual-agonist therapies, retatrutide acts as a triple agonist, synergistically
addressing multiple metabolic pathways:
GLP-1: Slows gastric emptying, enhances satiety, and regulates insulin release.
GIP: Improves insulin secretion and curbs hunger when paired with GLP-1.
Glucagon: Increases resting energy expenditure, helping to boost metabolism and break down fat cells.
Clinical Efficacy and Research - Clinical trials have demonstrated remarkable weight-loss outcomes, making it a highly anticipated therapeutic candidate for obesity and type 2 diabetes:
Weight Loss: Participants in Phase 2 trials lost an average of nearly 30% of their body weight (approximately 70 lbs) over an 80-week period.
Glycemic Control: It has shown significant potential in lowering HbA1c levels, with many patients with pre-diabetes returning to remission.
Metabolic Markers: Studies also indicate improvements in blood pressure, LDL cholesterol, and a reduction in liver fat.
Please allow 15-25 business days to be shipped
-
Supplied as a lyophilized powder vial, manufactured to the highest chemical standards. Every batch is strictly synthesized as a reference standard for laboratory evaluation, in-vitro testing, and scientific development purposes.
- Each lyophilized powder vial comes with 1 vial of reconstituting water, 5 alcohol pads and 5 individually wrapped syringes.
- Once reconstituted: DO NOT SHAKE. Roll between hands. Refrigerate. Dispose 30 days after reconstituted.
-
Laboratory Research Notice: This product is intended strictly for laboratory research and development use only. It is not for human consumption, therapeutic use, or veterinary applications.
